Healthcare / BiotechnologyTaipei Exchange
$16.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $10.5M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$246M
P/E
17.0x
↓EV/EBITDA
8.0x
↓ROE
6.0%
↑Gross Margin
44.6%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.9%
FCF CAGR
—
FCF margin
-5.6%
FCF / Net income
-0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $177.4M · net income $14.5M · FCF $-9.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $177.4M | $177.4M | $171.1M | $180.6M | $193.5M |
| Net Income | $14.5M | $14.5M | $16.6M | $22.8M | $24.6M |
| EBITDA | $29.2M | $29.2M | $29.8M | $34.8M | $36.8M |
| EPS | — | — | 1.07 | 1.47 | 1.60 |
| Gross Margin | 44.6% | 44.6% | 45.1% | 44.7% | 43.1% |
| Operating Margin | 7.8% | 7.8% | 9.4% | 13.4% | 14.0% |
| Net Margin | 8.2% | 8.2% | 9.7% | 12.6% | 12.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.03 | 0.05 | 0.06 |
| Current Ratio | 5.14 | 5.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.9M | $-9.9M | $10.5M | $14.0M | $28.2M |
| Returns | |||||
| ROE | 6.0% | 6.0% | 6.9% | 9.6% | 10.4% |
| Valuation | |||||
| P/E | 17.02 | 17.02 | 18.50 | 15.61 | 12.31 |
| EV/EBITDA | 8.02 | 8.02 | 9.66 | 9.62 | 6.81 |
| P/B | 1.03 | 1.03 | 1.28 | 1.49 | 1.28 |
| Growth & Yield | |||||
| Revenue Growth | 3.7% | 3.7% | -5.2% | -6.7% | — |
| EPS Growth | — | — | -27.2% | -8.1% | — |
| Dividend Yield | 5.9% | 5.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.3%
Start / end P/E
n/dx → n/dx
EPS bridge
1.07 → n/d
Residual
-16.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.